Dry Eye Syndrome Clinical Trial
Verified date | May 2012 |
Source | Alcon Research |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to evaluate the ocular retention time of Systane Ultra compared to Hialid and saline.
Status | Completed |
Enrollment | 27 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosed with mild to moderate dry eye as defined in the protocol. - Able and willing to follow instructions. - Other protocol-defined inclusion criteria may apply. Exclusion Criteria: - Any medical condition that may affect the results of the study. - History or evidence of ocular or intraocular surgery within the past six months. - History of intolerance or hypersensitivity to any component of the study medications. - Use of concomitant topical ocular medications during the study period. - Ocular conditions that may preclude safe administration of the test article. - Unwilling to discontinue contact lens wear during the study period. - Participation in an investigational drug or device study within 30 days of enrollment. - Other protocol-defined exclusion criteria may apply. |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Alcon Research |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ocular surface residence time | Ocular surface residence time is defined as the time for fluorescence intensity to return to baseline value after a drop of ophthalmic dye is instilled in the study eye. Dye retention will be measured with a fluorophotometer. | Time to event | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02522312 -
A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients
|
N/A | |
Completed |
NCT02597803 -
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
|
Phase 2/Phase 3 | |
Completed |
NCT01863368 -
Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining
|
N/A | |
Completed |
NCT01753752 -
Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation
|
Phase 2 | |
Completed |
NCT01753687 -
Correlation of Different Signs for Assessment of Dry Eye Syndrome
|
N/A | |
Completed |
NCT01212471 -
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
|
Phase 3 | |
Completed |
NCT01198782 -
Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%
|
Phase 4 | |
Completed |
NCT01162954 -
Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00535054 -
Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms
|
N/A | |
Completed |
NCT00544713 -
Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery
|
N/A | |
Completed |
NCT00344721 -
A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome
|
N/A | |
Completed |
NCT03830359 -
Efficacy, Safety of T2769 in Dry Eye Disease
|
N/A | |
Completed |
NCT04139122 -
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02758327 -
Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops
|
Phase 4 | |
Completed |
NCT01970917 -
Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects
|
Phase 4 | |
Completed |
NCT02066051 -
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
|
N/A | |
Completed |
NCT02092207 -
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT01541891 -
Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT00765804 -
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
|
Phase 2 | |
Completed |
NCT00514852 -
Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye
|
N/A |